Society of Hematologic Oncology Annual Meeting (SOHO)

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Loncastuximab tesirine-lpyl plus rituximab demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma.

The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.

Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.

A retrospective analysis of the Surveillance, Epidemiology, and End Results database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis.

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

No difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hematopoietic stem cell transplantation in elderly patients over the age of 60 with acute myeloid leukemia in first complete remission.

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.

The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Varying outcomes were observed among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were treated with pediatric-inspired protocols vs adult chemotherapy regimens.

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.

Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

Ivosidenib plus venetoclax with or without azacitidine showed an expected and tolerable safety profile with durable responses and a prolonged survival rate across acute myeloid leukemia disease groups.

Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.

Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.